bit.bio’s opti-ox precision cell programming technology is used to control the expression of TF combinations within Treg cell therapies. Credit: Design_Cells / Shutterstock.com.

BlueRock Therapeutics has signed a collaboration and option agreement with bit.bio to discover and manufacture iPSC (induced pluripotent stem cell)-derived regulatory T cells (Tregs)-based therapies.

bit.bio will detect transcription factor (TF) combinations to reprogramme iPSCs into Tregs by leveraging its machine learning (ML) powered discovery platform.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The agreement also provides BlueRock options to license bit.bio’s opti-ox precision cell programming technology, which is used for controlling the expression of TF combinations within Treg cell therapies.

The opti-ox technology leverages a dual genomic, safe harbour approach to cell programming.

By deploying opti-ox, bit.bio will rapidly facilitate the TF-mediated transformation of iPSCs into highly defined cell types in one step.

See Also:

bit.bio founder and CEO Mark Kotter stated: “Today’s announcement marks an important milestone for bit.bio. As well as providing significant financial contributions, our collaboration is a testament to the unique capabilities of bit.bio’s team.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BlueRock is tasked with the global development and commercialisation of therapeutic candidates resulting from the partnership.

bit.bio will receive an upfront payment, then further milestone payments and royalties on global sales of all therapies emerging from the collaboration.

BlueRock Therapeutics chief scientific officer Stefan Irion stated: “iPSC-derived Treg-based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders, and we look forward to collaborating with the bit.bio team to explore how their opti-ox cell programming technology can accelerate our efforts to discover and manufacture Tregs from iPSCs.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.